# Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

> **NCT03298867** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 83 (actual)

## Conditions studied

- Thyroid Eye Disease
- Graves' Orbitopathy

## Interventions

- **BIOLOGICAL:** Teprotumumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03298867
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-04
- **Primary completion:** 2019-02-13
- **Final completion:** 2020-11-30
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298867, "Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03298867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*